LATEST BVE NEWS
Don Casey, Veteran Healthcare Exec, Joins Bonaventure Equity’s Board Pioneering Cannabinoid and Psychedelic Medicine
Bonaventure Equity (“BVE”), a pioneering force in the world of healthcare and pharmaceutical venture capital, is thrilled to announce the addition of Don Casey to their Board of Advisors. Casey brings a wealth of health care experience that has included roles as a former Johnson & Johnson Executive Committee Member and multiple CEO and board positions of multiple health care companies. He will provide valuable perspective and strategic insight to BVE as the company bridges funding gaps in cannabinoid and psychedelic medicinal and clinical research, ushering in a new era of innovative treatments to tackle healthcare’s biggest challenges.
FloraWorks Appoints BVE’s Dr. Mike McCormick VP of Strategy
FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced the appointment of Dr. Mike McCormick as VP of Strategy. A science and intellectual property consultant for FloraWorks since 2022, Dr. McCormick brings extensive expertise in cannabinoid biochemistry, innovation, and IP protection.
Bonaventure Equity Announces Investment of FloraWorks
FloraWorks Holdings Inc. (the “Company” or “FloraWorks”), a biotech company specializing in rare and novel cannabinoids, is pleased to announce the initial closing of its Series A financing with its lead investor BVE Select Fund II, L.P., the second life sciences venture fund of Bonaventure Equity, LLC (“BVE”). BVE’s Founder and Managing Partner, Ross O’Brien, will be joining the Company’s board of directors. This latest round of funding will support FloraWork’s efforts in bringing the therapeutic benefits of cannabinoids to the forefront of modern medicine.
Bonaventure Equity Announces Investment of Sensorium Therapeutics
BVE is excited to welcome Sensorium Therapeutics, a leading medical development platform focused on psychoactive drugs, to the BVE Fund II portfolio. This investment represents our commitment to identifying and investing in world class life sciences teams.
BVE Psychedelic Investment & Policy Summit
Join BVE at this invitation-only happy hour event featuring leading scientists and policymakers to discuss The Role of Government & The Future of Healthcare. Thursday, November 17, 2022 5:30pm - 7:30pm. Click below to view our guest speakers’ bios.
BVE Announces Follow On Investment in Nalu Bio
Nalu Bio, Inc., is creating a new category of cannabinoids, fundamentally disrupting their agricultural production for the wellness and pharmaceutical markets.
A top cannabis and psychedelics investor predicts an ‘existential crisis’ ahead for startups and shares 2 key pieces of advice for founders
Read the full article at BusinessInsider.com. Premium membership required.
Alternatively, click the button to download the full article.
Bonaventure Equity Announces Follow-On Investment in Engineered Medical Technologies (tCheck)
RALEIGH, NC, May 26, 2022 - Bonaventure Equity, LLC (“BVE”) is pleased to announce the first investment from its botanical life sciences venture fund, BVE Select Fund II, L.P., in Engineered Medical Technologies, Inc. (“tCheck”). BVE made a seed stage investment in tCheck in 2020 from its first fund and with this follow-on investment BVE’s Founder and Managing Partner, Ross O’Brien, will be joining tCheck’s Board of Directors.
A VC who's raising $30 million lays out why he's betting on cannabis life-science companies to avoid the sector's 'irrational exuberance'
Read the full article at BusinessInsider.com. Premium membership required.
Alternatively, click the button to download the full article.
Bonaventure Equity Announces the Appointment of Robert J. Toth, Jr. to the Position of Scientific Operating Partner
RALEIGH, NC, April 11, 2022 - Bonaventure Equity, LLC (“BVE”), a cannabis and psilocybin life sciences venture capital firm, is pleased to announce Robert J. Toth, Jr. has joined BVE as a Scientific Operating Partner for its second fund, BVE Select Fund II, L.P.. A seasoned executive and advisor, Mr. Toth has two decades’ experience within the biotechnology industry, adding significantly to BVE’s industry depth and expertise.
Bonaventure Equity Announces Addition of Daniel Levin, CEO of Prominent Brand+Talent as an Operating Advisor
RALEIGH, NC, March 24, 2022 - Bonaventure Equity, LLC (“BVE”), a cannabis and psilocybin life sciences venture capital firm, is pleased to announce the addition of Daniel Levin, CEO and Managing Member of Los Angeles based Prominent Brand+Talent as an operating advisor.
Bonaventure Equity Announces the First Close of Life Sciences Cannabis Venture Fund
RALEIGH, NC, March 8, 2022 – Bonaventure Equity, LLC (“BVE”), a life sciences venture capital firm focused on innovation in the cannabis economy, has announced the first closing of its second cannabis venture fund, BVE Select Fund II, L.P. (“Fund II”).
Biotechs are betting millions on developing synthetic cannabis compounds in a race to capture a slice of a $115 billion market
Read the full article at BusinessInsider.com. Premium membership required.
Alternatively, click the button to download the full article.
Interview with TJ Stouder of HoliSTIK Wellness | BVE Portfolio Company
TJ is a former Procter & Gamble executive and the quintessential entrepreneur who encountered a problem and found an innovative solution. The result is a bespoke line of CBD Wellness (TM) products. In our recent Q&A, TJ discusses the importance of transparency and the booming CBD beverage market.
